2010 full-year results 3 March 2011 - UCB

More documents

Recommendations

Info

Vimpat ® in epilepsy When monotherapy is no longer enough… Epilepsy adjunctive therapy When monotherapy is no longer enough… • A new treatment option in add-on for POS 1 • Efficacy when added to broad range of 1 st and 2 nd generation AEDs 2 • Additional efficacy with manageable side effects • Sustainable – high long-term retention rate demonstrated by Vimpat ® open label extension trial • No drug-drug interactions; multiple formulations Net sales increased by 133 % € million Europe ROW <strong>2010</strong> net sales 36 1 2009 net sales 16 ~ 49 000 patients on Vimpat ® 0 1 Partial onset seizures 2 Anti-epileptic drug 22
Vimpat ® in epilepsy Roll-out in Europe and Rest of World 12 9 6 3 0 Quarterly sales evolution since launch € million Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2008 2009 <strong>2010</strong> 23
Page 1 and 2: 2010 full-year results 3 March 2011
Page 3 and 4: UCB: to be patient-centric global b
Page 5 and 6: 203 000 patients have now been trea
Page 7 and 8: U.S. Business Greg Duncan, Presiden
Page 9 and 10: Cimzia ® provides a fast response
Page 11 and 12: Cimzia ® in rheumatoid arthritis -
Page 13 and 14: Vimpat ® U.S. When monotherapy is
Page 15 and 16: UCB’s status as the company with
Page 17 and 18: Physicians report Vimpat ® is the
Page 19 and 20: Cimzia ® Fast response for predict
Page 21: Cimzia ® roll-out in Europe and Re
Page 25 and 26: Neupro ® roll-out in Europe and Re
Page 27 and 28: Neupro ® - rotigotine transdermal
Page 29 and 30: 2010 Financial Performance Detlef T
Page 31 and 32: Net sales of major and new products
Page 33 and 34: Recurring EBITDA Consistent solid u
Page 35 and 36: 2010 cash flows FY 2009 cash € 46
Page 37 and 38: 2011 financial outlook Revenue is e
Page 39 and 40: Advancing the pipeline Iris Loew-Fr
Page 41 and 42: Development pipeline with significa
Page 43 and 44: Brivaracetam in epilepsy New Phase
Page 45 and 46: Additional external pipeline option
Page 47 and 48: UCB NewMedicines strategy and busin
Page 49 and 50: Attrition rates of failed Phase 3 c
Page 51 and 52: UCB2892 (H3 antagonist) January 201
Page 53 and 54: Significant Pipeline Q2 January pip
Page 55 and 56: UCB's Sustainable Growth Roch Doliv
Page 57 and 58: UCB's sustainable future growth Cim
Page 59 and 60: Appendix 59 59
Page 61 and 62: Geographic and therapeutic breakdow
Page 63 and 64: 2010 balance sheet € million Cash
Page 65 and 66: Shareholder structure 1 Strong and
Page 67 and 68: Cimzia ® in further arthritis indi
Page 69 and 70: CDP7851 in bone loss disorders Nove
Page 71 and 72: Vimpat ® in epilepsy Increasing pa
Page 73:
Your UCB Investor Relations team An
show all

2010 full-year results 3 March 2011 - UCB

Create successful ePaper yourself

Delete template?

Save as template?